Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "neuropsychiatric"

7 News Found

AbbVie and Gedeon Richter to collaborate on neuropsychiatric diseases
Biotech | March 11, 2022

AbbVie and Gedeon Richter to collaborate on neuropsychiatric diseases

Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products


MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain
Clinical Trials | October 29, 2025

MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain

Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation


Aptar Pharma partners with Dianosic to advance ARIS platform for treatment of chronic allergic rhinitis and rhinosinusitis
News | September 08, 2025

Aptar Pharma partners with Dianosic to advance ARIS platform for treatment of chronic allergic rhinitis and rhinosinusitis

Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods


MIRA Pharmaceuticals announces collaboration with Pharmaseed
News | February 08, 2024

MIRA Pharmaceuticals announces collaboration with Pharmaseed

Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024


Mindset Pharma to defend against lawsuit filed by Reunion Neurosciences
News | March 17, 2023

Mindset Pharma to defend against lawsuit filed by Reunion Neurosciences

Mindset disagrees with and denies the allegations set forth from Reunion.


AbbVie acquires Syndesi Therapeutics, strengthening neuroscience portfolio
News | March 04, 2022

AbbVie acquires Syndesi Therapeutics, strengthening neuroscience portfolio

Expands AbbVie's neuroscience portfolio, adding first-in-class modulators of the synaptic vesicle protein 2A, including lead molecule SDI-118 currently in Phase 1b studies


Lo.Li Pharma International seeks partners for Deplesin therapy
Biotech | December 15, 2021

Lo.Li Pharma International seeks partners for Deplesin therapy

Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot